Cumming School of Medicine, Department of Pediatrics, University of Calgary, Calgary, Alberta, Canada.
Alberta Research Centre for Health Evidence, Department of Pediatrics, University of Alberta, Edmonton, Alberta, Canada.
JAMA Pediatr. 2021 Oct 1;175(10):e212328. doi: 10.1001/jamapediatrics.2021.2328. Epub 2021 Oct 4.
Detection of Clostridioides difficile has frequently been described in asymptomatic infants and children, but accurate estimates across the age spectrum are unavailable.
To assess the prevalence of C difficile detection among asymptomatic children across the age spectrum.
This systematic review and meta-analysis included a search of the Cochrane Central Register of Controlled Trials, MEDLINE, Embase, CINAHL, Scopus, and Web of Science for articles published from January 1, 1990, to December 31, 2020. Search terms included Clostridium difficile, Peptoclostridium difficile, Clostridioides difficile, CDF OR CDI OR c diff OR c difficile, Clostridium infections OR cd positive diarrhea OR cd positive diarrhea OR Clostridium difficile OR Peptoclostridium difficile OR pseudomembranous colitis OR pseudomembranous enterocolitis, enterocolitis, and pseudomembranous. These were combined with the following terms: bacterial colonization and colonization OR colonized OR colonizing OR epidemiology OR prevalence OR seroprevalence.
Studies were screened independently by 2 authors. Studies were included if they reported testing for C difficile among asymptomatic children (ie, children without diarrhea) younger than 18 years.
Data were extracted independently and in duplicate by 2 reviewers. Preferred Reporting Items for a Systematic Review and Meta-analysis (PRISMA) guidelines were used. Data were pooled using a random-effects model.
The primary outcome was prevalence of C difficile detection among asymptomatic children. Secondary outcomes included prevalence of toxigenic vs nontoxigenic strains of C difficile and prevalence of C difficile detection stratified by geographic region, income status, testing method, and year of testing.
A total of 95 studies with 19 186 participants were included. Rates of detection of toxigenic or nontoxigenic C difficile were greatest among infants aged 6 to 12 months (41%; 95% CI, 32%-50%) and decreased to 12% (95% CI, 7%-18%) among children aged 5 to 18 years. The prevalence of toxigenic C difficile colonization was lower, peaking at 14% (95% CI, 8%-21%) among infants aged 6 to 12 months and decreasing to 6% (95% CI, 2%-11%) among children older than 5 years. Although prevalence differed by geographic region (ie, North and South America vs Europe: β, -0.151, P = .001; North and South America vs Western Pacific: β, 0.136, P = .007), there was no difference by testing method (ie, culture vs polymerase chain reaction: β, 0.069, P = .052; culture vs enzyme immunoassay: β, -0.178, P = .051), income class (low-middle income vs high income: β, -0.144, P = .23; upper-middle vs high income: β, -0.020, P = .64), or period (before 1990 vs 2010-2020: β, -0.125, P = .19; 1990-1999 vs 2010-2020: β, -0.037, P = .42; 2000-2009 vs 2010-2020: β, -0.006, P = .86).
In this systematic review and meta-analysis, C difficile colonization rates among children were greatest at 6 to 12 months of age and decreased thereafter. These estimates may provide context for interpreting C difficile test results among young children.
已有研究频繁报道了无症状婴儿和儿童中艰难梭菌的检出情况,但针对各年龄段的准确估计数据尚不可用。
评估各年龄段无症状儿童中艰难梭菌检测的流行率。
本系统评价和荟萃分析纳入了从 1990 年 1 月 1 日至 2020 年 12 月 31 日发表的 Cochrane 对照试验注册中心、MEDLINE、Embase、CINAHL、Scopus 和 Web of Science 的文章进行搜索。检索词包括艰难梭菌、艰难梭状芽胞杆菌、艰难梭菌、CDF 或 CDI 或 c 差或 c 困难、艰难梭菌感染或 cd 阳性腹泻或 cd 阳性腹泻或艰难梭菌或艰难梭状芽胞杆菌或伪膜性结肠炎或伪膜性肠炎、肠炎和伪膜性、细菌定植和定植或定植或定植或流行病学或流行率或血清流行率。这些与以下术语结合使用:细菌定植和定植或定植或定植或流行病学或流行率或血清流行率。
两名作者独立筛选研究。如果研究报告了对年龄小于 18 岁且无腹泻的无症状儿童(即无症状儿童)进行艰难梭菌检测,则纳入研究。
两名评审员独立并重复提取数据。采用首选报告项目(PRISMA)指南。使用随机效应模型对数据进行汇总。
主要结局为无症状儿童中艰难梭菌检测的流行率。次要结局包括产毒与非产毒艰难梭菌的流行率以及艰难梭菌检测的流行率,按地理位置、收入状况、检测方法和检测年份进行分层。
共纳入 95 项研究,涉及 19 186 名参与者。6 至 12 个月大婴儿的产毒或非产毒艰难梭菌检出率最高(41%,95%CI,32%-50%),5 至 18 岁儿童的检出率降至 12%(95%CI,7%-18%)。艰难梭菌定植的产毒率较低,6 至 12 个月大婴儿的产毒率最高(14%,95%CI,8%-21%),5 岁以上儿童的产毒率降至 6%(95%CI,2%-11%)。尽管地理位置(北美和南美与欧洲:β,-0.151,P=0.001;北美和南美与西太平洋:β,0.136,P=0.007)存在差异,但检测方法(即培养与聚合酶链反应:β,0.069,P=0.052;培养与酶免疫测定:β,-0.178,P=0.051)、收入类别(中低收入与高收入:β,-0.144,P=0.23;中上收入与高收入:β,-0.020,P=0.64)或时间(1990 年前与 2010-2020 年:β,-0.125,P=0.19;1990-1999 年与 2010-2020 年:β,-0.037,P=0.42;2000-2009 年与 2010-2020 年:β,-0.006,P=0.86)均无差异。
在本系统评价和荟萃分析中,儿童艰难梭菌定植率在 6 至 12 个月龄时最高,此后逐渐下降。这些估计结果可能为解读幼儿艰难梭菌检测结果提供了依据。